To investigate the feasibility of inguinal hernia repair in patients at stable stage of malignant tumors.

A total of 10 964 hospitalized patients with inguinal hernia from 58 hospitals during January 1st, 2017 to December 31st, 2017 were included and divided into 4 groups according to surgical technique and whether the patient had a history of malignant tumor: (1) LM⁺, laparoscopic hernia repair on patients with malignant tumor; (2) OM⁺, open hernia repair on patients with malignant tumor; (3) LM^-, laparoscopic hernia repair on patients without malignant tumor; (4) OM^-, open hernia repair on patients without malignant tumor. The perioperative parameters were retrospectively compared.

The time of operation, the volume of intraoperative bleeding and the incidence of perioperative adverse events (hemorrhage, seroma and VTE) in LM⁺ group were (71.05±33.64) minutes vs (77.04±35.68) minutes, (7.82±5.46) ml vs (8.06±7.36) ml, (3.62% vs 2.67%), (3.62% vs 2.37%), (0 vs 0.25%), respectively, compared with LM^-, there were not statistically different (P>0.05); the time of operation, the volume of intraoperative bleeding and the incidence of perioperative adverse events (hemorrhage, seroma and VTE) in OM⁺ group were (76.00±34.69) minutes vs (79.65±42.07) minutes, (7.56±6.41) ml vs (8.33±7.96) ml, (0.70% vs 2.19%), (2.44% vs 2.19%), (0 vs 0.02%), respectively, compared with OM^-, there were not statistically different (P>0.05).

Judging from the perioperative parameters, inguinal hernia repair is safe and feasible to be performed on patients with malignant tumor, and this study can provide some evidences and guidance for clinical management.